Researchers wanted to find out if ivermectin compared to placebo shortened symptom duration for adult patients in the United States with symptomatic mild to moderate COVID-19. According to results of the randomized clinical trial published in JAMA on October 21, 2022, the research team found that among outpatients with mild to moderate COVID-19, treatment with ivermectin compared with placebo did not significantly improve time to recovery